TELO — Telo Genomics Balance Sheet
0.000.00%
- CA$9.00m
- CA$6.75m
Annual balance sheet for Telo Genomics, fiscal year end - June 30th, CAD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | — | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.921 | 3.64 | 2.69 | 2.67 | 0.796 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.049 | 0.097 | 0.038 | 0.064 | 0.031 |
Prepaid Expenses | |||||
Total Current Assets | 1.04 | 3.76 | 2.79 | 2.84 | 0.919 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.115 | 0.062 | 0.03 | 0.066 | 0.03 |
Net Intangible Assets | |||||
Total Assets | 1.17 | 3.84 | 2.83 | 2.93 | 0.966 |
Payable / Accrued | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 0.353 | 0.114 | 0.19 | 0.28 | 0.376 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 0.393 | 0.154 | 0.23 | 0.313 | 0.376 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 0.775 | 3.69 | 2.6 | 2.61 | 0.59 |
Total Liabilities & Shareholders' Equity | 1.17 | 3.84 | 2.83 | 2.93 | 0.966 |
Total Common Shares Outstanding |